<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pediatric chronic kidney disease-mineral and bone disorder (CKD-MBD)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pediatric chronic kidney disease-mineral and bone disorder (CKD-MBD)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pediatric chronic kidney disease-mineral and bone disorder (CKD-MBD)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tarak Srivastava, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley A Warady, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 20, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Abnormalities in mineral metabolism and bone structure are an almost universal finding with progressive chronic kidney disease (CKD) [<a href="#rid1">1</a>]. Abnormal regulation of mineral metabolism in children with CKD results in significant complications similar to those seen in adult patients (eg, fractures, bone pain, and avascular necrosis) and others that are unique to children (eg, growth failure and skeletal deformities).</p><p>The diagnosis, prevention, and management of pediatric CKD-mineral and bone disorder (CKD-MBD) will be reviewed here. CKD-MBD in adults is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a> and  <a class="medical medical_review" href="/d/html/114322.html" rel="external">"Osteoporosis in patients with chronic kidney disease: Management"</a> and  <a class="medical medical_review" href="/d/html/91082.html" rel="external">"Adynamic bone disease associated with chronic kidney disease"</a> and  <a class="medical medical_review" href="/d/html/1964.html" rel="external">"Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H61630351"><span class="h1">DEFINITION</span></p><p class="headingAnchor" id="H822541286"><span class="h2">Chronic kidney disease (CKD)</span><span class="headingEndMark"> — </span>In the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines, the diagnosis of CKD is based on fulfilling <strong>one</strong> of the following criteria [<a href="#rid2">2</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Glomerular filtration rate (GFR) of less than 60 mL/min per 1.73 m<sup>2</sup> for greater than three months with implications for health regardless of whether other CKD markers are present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>GFR greater than 60 mL/min per 1.73 m<sup>2</sup> that is accompanied by evidence of structural damage or other markers of functional kidney abnormalities, including proteinuria, albuminuria, renal tubular disorders, or pathologic abnormalities detected by histology or inferred by imaging.</p><p></p><p>In addition, the KDIGO guidelines define CKD staging for children older than two years of age, which stratifies the risk for progression of CKD and its complications based on GFR. This classification is used in this topic to guide management, including what therapeutic interventions should be initiated and when  (<a class="graphic graphic_table graphicRef89808" href="/d/graphic/89808.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Stage G1 – Normal GFR (≥90 mL/min per 1.73 m<sup>2</sup>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage G2 – GFR between 60 and 89 mL/min per 1.73 m<sup>2</sup></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage G3a – GFR between 45 and 59 mL/min per 1.73 m<sup>2</sup></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage G3b – GFR between 30 and 44 mL/min per 1.73m<sup>2</sup></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage G4 – GFR between 15 and 29 mL/min per 1.73 m<sup>2</sup></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage G5 – GFR of &lt;15 mL/min per 1.73 m<sup>2</sup> (kidney failure) requiring kidney replacement therapy (ie, dialysis or kidney transplantation)</p><p></p><p>Children under two years of age do not fit within the above classification system because they normally have a low GFR even when corrected for body surface area. In these patients, calculated GFR based upon serum creatinine can be compared with normative age-appropriate values to detect kidney impairment. The KDIGO guideline suggests that a GFR value &gt;1 standard deviation below the mean should raise concern and prompt more intensive monitoring  (<a class="graphic graphic_table graphicRef55965" href="/d/graphic/55965.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/6115.html" rel="external">"Chronic kidney disease in children: Definition, epidemiology, etiology, and course", section on 'Estimated glomerular filtration rate'</a>.)</p><p class="headingAnchor" id="H1815682360"><span class="h2">CKD-MBD</span><span class="headingEndMark"> — </span>In 2006, the Kidney Disease: Improving Global Outcomes (KDIGO) group, an international collaboration of nephrology experts who developed guidelines to improve the care of patients with CKD, recommended using the term CKD-MBD to describe the systemic bone disorder associated with CKD [<a href="#rid3">3</a>]. In this topic, the definition of CKD-MBD in children is manifested by one or a combination of the following three components, which are similar to those used in adult patients with CKD:</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities of calcium, phosphorus, parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and vitamin D metabolism</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities in bone turnover, mineralization, volume linear growth, or strength</p><p class="bulletIndent1"><span class="glyph">●</span>Extraskeletal calcification</p><p></p><p>The previously used term "renal osteodystrophy" exclusively defines alterations in bone morphology associated with CKD based upon bone biopsy [<a href="#rid4">4</a>]. (See <a class="local">'Bone pathology'</a> below.)</p><p class="headingAnchor" id="H3356212172"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H1876265705"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Clinical manifestations of CKD-MBD vary based on the severity of CKD and whether interventions to prevent MBD have been instituted. CKD-MBD, when untreated, can first be detected in children with stage G2 CKD. Although these patients typically have no signs or symptoms related to bone disease, they often have abnormal laboratory levels of serum calcium, phosphorus, parathyroid hormone (PTH), and 1,25-dihydroxyvitamin D. Untreated patients with more severe CKD (stage G3 through G5) become increasingly symptomatic with bone pain, fractures, difficulty in walking, and/or skeletal deformities such as varus and valgus deformities of the long bones.</p><p class="headingAnchor" id="H2667977732"><span class="h2">Complications</span><span class="headingEndMark"> — </span>Children with CKD are at-risk for the following complications of CKD-MBD:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growth failure</strong> – MBD, along with several other factors including chronic metabolic acidosis, anorexia and inadequate caloric intake, inadequate unbound insulin-like growth factor, and/or the primary kidney disease, may contribute to poor growth in children with advanced CKD. The relative importance of these factors in growth failure is uncertain. (See  <a class="medical medical_review" href="/d/html/14555.html" rel="external">"Growth failure in children with chronic kidney disease: Risk factors, evaluation, and diagnosis", section on 'Contributing factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rickets</strong> – Depending on the patient age and severity of disease, patients may present with rickets with its well-defined clinical (eg, parietal and frontal bossing and widening of wrists) and radiologic features (eg, osteopenia, widening of the epiphyseal plate, and cupping, splaying, and fraying of metaphysis). (See  <a class="medical medical_review" href="/d/html/5856.html" rel="external">"Overview of rickets in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fractures</strong> – The risk for fracture is increased two- to threefold in children with CKD compared with the general pediatric population [<a href="#rid5">5</a>]. In a retrospective cohort study of 537 children with CKD, advanced pubertal stage, greater height Z-score, difficulty walking, and higher average log-transformed PTH level were independently associated with greater fracture risk, while calcium-based phosphate binder treatment was associated with lower fracture risk [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Slipped epiphysis and genu valgum</strong> – In children with CKD, the growth plate is vulnerable to injury with disruption of the connection between the epiphyseal plate and the metaphysis [<a href="#rid6">6</a>]. This abnormality, along with hyperparathyroid erosions of bone, puts the child at an increased risk for slipped epiphysis and genu valgum. (See  <a class="medical medical_review" href="/d/html/6554.html" rel="external">"Evaluation and management of slipped capital femoral epiphysis (SCFE)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extraskeletal calcification</strong> – Extraskeletal soft tissue calcifications (also called calcinosis) include vascular, ocular, periarticular, and visceral calcifications. Limited data in children have reported soft tissue calcification within the coronary arteries [<a href="#rid7">7-13</a>]. Vascular calcification is accelerated in children on hemodialysis [<a href="#rid14">14</a>], is associated with abnormalities of circulating calcification inhibitors [<a href="#rid15">15</a>], and worsens with severity of mineral bone abnormalities, including elevation of fibroblast growth factor 23 (FGF23) and dialysis duration [<a href="#rid16">16-18</a>]. (See  <a class="medical medical_review" href="/d/html/7222.html" rel="external">"Vascular calcification in chronic kidney disease"</a> and  <a class="medical medical_review" href="/d/html/1944.html" rel="external">"Calciphylaxis (calcific uremic arteriolopathy)"</a>.)</p><p></p><p class="bulletIndent1">In an attempt to minimize the risk of soft tissue and vascular calcification, the Pediatric Renal Nutrition Taskforce recommends targeting serum calcium and phosphorus levels within the age-appropriate normal range [<a href="#rid19">19</a>]:</p><p></p><p class="headingAnchor" id="H2964989719"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Untreated or inadequately treated CKD-MBD is manifested by the following laboratory abnormalities:</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperphosphatemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased serum 1,25-dihydroxyvitamin D levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum calcium abnormalities – Untreated CKD-MBD presents with hypocalcemia. However, hypercalcemia may be a complication of CKD-MBD therapeutic interventions or tertiary hyperparathyroidism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated serum parathyroid hormone (PTH) levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated serum alkaline phosphatase (ALP) levels.</p><p></p><p class="headingAnchor" id="H3866456978"><span class="h3">Phosphate retention and secondary hyperparathyroidism</span><span class="headingEndMark"> — </span>In pediatric CKD, phosphate retention with advanced kidney disease results in 1,25-dihydroxyvitamin D deficiency, hypocalcemia, and secondary hyperparathyroidism. Phosphate retention and 1,25-dihydroxyvitamin D deficiency decrease serum calcium and contribute directly to secondary hyperparathyroidism. Secondary hyperparathyroidism results in increased bone turnover and abnormalities in bone morphology (ie, renal osteodystrophy). Hyperparathyroidism does initially increase urinary phosphate excretion in the early stages of CKD, but this adaptation becomes inadequate as CKD advances, resulting in hyperphosphatemia if not treated. (See  <a class="medical medical_review" href="/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Abnormalities of parathyroid hormone, calcium, phosphorus, fibroblast growth factor 23, and vitamin D metabolism'</a>.)</p><p>Phosphate retention begins early in CKD as the decline in glomerular filtration rate (GFR) decreases the filtered phosphate load, resulting in a decrease in renal phosphate excretion, and leads to an increased FGF23 level. FGF23 inhibits 1-hydroxylase activity in the kidney, causing a reduction in 1,25-dihydroxyvitamin D levels from decreased 1-hydroxylation of 25-hydroxyvitamin D. The clinical implications of the pathophysiologic changes are that a child with CKD in late-stage G2 and in stage G3 disease may have normal serum calcium and phosphorus levels that are maintained in the normal range by an elevated serum PTH level. When the GFR falls below 30 mL/min per 1.73 m<sup>2</sup> (stage G4 disease and beyond), hyperphosphatemia (levels above the normal range) and hypocalcemia will usually occur unless appropriate therapy is given.</p><p class="headingAnchor" id="H3995196376"><span class="h2">Bone pathology</span><span class="headingEndMark"> — </span>Renal osteodystrophy is defined as alterations in bone morphology due to abnormalities of bone turnover and mineralization and is one of the components of CKD-MBD [<a href="#rid2">2,3</a>]. Although bone biopsy is costly, invasive, and is rarely performed clinically, it remains the gold standard to diagnose bone disease [<a href="#rid20">20</a>]. It represents the historical changes in MBD, which may be in a state of flux depending on of the course of CKD and treatment changes. Several biomarkers, including serum PTH, calcium, phosphorus, 25-hydroxyvitamin D, and ALP levels have been used to monitor alterations in bone turnover and mineralization; however, they have had limited success [<a href="#rid20">20</a>].</p><p>In children with CKD, renal osteodystrophy based on bone biopsy is classified into the following subtypes, which are also seen in adult patients with CKD [<a href="#rid21">21-23</a>] (see  <a class="medical medical_review" href="/d/html/7239.html" rel="external">"Evaluation of renal osteodystrophy"</a>). The severity of bone disease rises with the progression of CKD and children undergoing chronic dialysis have the most severe bone disease [<a href="#rid24">24</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteitis fibrosa cystica</strong> – Osteitis fibrosa cystica is characterized by high bone turnover due to secondary hyperparathyroidism  (<a class="graphic graphic_picture graphicRef63957" href="/d/graphic/63957.html" rel="external">picture 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adynamic bone disease</strong> – Adynamic bone disease is characterized by low bone turnover with reductions in both osteoblast and osteoclast activity due to excessive suppression of the parathyroid glands by medication  (<a class="graphic graphic_picture graphicRef75592" href="/d/graphic/75592.html" rel="external">picture 2</a>). This represents the major bone lesion in peritoneal dialysis and hemodialysis adult patients. (See  <a class="medical medical_review" href="/d/html/91082.html" rel="external">"Adynamic bone disease associated with chronic kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteomalacia</strong> – Osteomalacia is characterized by low bone mineralization  (<a class="graphic graphic_picture graphicRef61773" href="/d/graphic/61773.html" rel="external">picture 3</a>). Osteomalacia, which is now uncommon, was due primarily to aluminum deposition in bone at a time when aluminum-containing antacids were used as phosphate binders. The incidence of osteomalacia has decreased with the abandonment of aluminum-based phosphate binders and the use of efficient techniques in water treatment for preparing dialysate. However, osteomalacia can still be seen in children who have inadequate intake of substrate (calcium and phosphate) or increased renal tubular losses. (See  <a class="medical medical_review" href="/d/html/1839.html" rel="external">"Aluminum toxicity in chronic kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mixed uremic osteodystrophy</strong> – Mixed uremic osteodystrophy describes bone biopsy findings of both high bone turnover and a disproportionate decrease in mineralization resulting in increased osteoid  (<a class="graphic graphic_picture graphicRef52703" href="/d/graphic/52703.html" rel="external">picture 4</a>). As in osteitis fibrosa cystica, the high bone turnover is mediated by increases in both osteoblast and osteoclast activity. In contrast to osteitis fibrosa cystica, the marked decrease in mineralization suggests a concomitant mineralization defect.</p><p></p><p class="headingAnchor" id="H62691477"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of pediatric CKD-MBD is made upon fulfilling one of the criteria for the definition of CKD-MBD. This typically occurs when a laboratory abnormality of bone mineralization (eg, calcium, phosphorus, or parathyroid hormone) is detected during ongoing screening/monitoring of children with CKD stages 2 through 4. </p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities of calcium, phosphorus, parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and vitamin D metabolism</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities in bone turnover, mineralization, volume linear growth, or strength</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extraskeletal calcification</p><p></p><p>Bone biopsy is rarely performed clinically, but can confirm the diagnosis when there are changes consistent with renal osteodystrophy (ie, abnormalities of bone turnover and mineralization) (see <a class="local">'Bone pathology'</a> above). Indications for bone biopsy are not well established for children with CKD because it is not clear when a histological diagnosis of bone disease impacts clinical treatment decision making [<a href="#rid3">3,25</a>]. At our center, we do not perform bone biopsy to make the diagnosis of renal osteodystrophy. On the rare occasion when it is decided to perform a bone biopsy, we will refer the patient to a specialized center with particular expertise in preparing the subject and handling and interpreting the biopsy tissue. The site of biopsy is typically the iliac crest and the specimen is obtained after the administration of <a class="drug drug_pediatric" data-topicid="12830" href="/d/drug information/12830.html" rel="external">tetracycline</a> markers, which are used to determine the rate of new bone formation. </p><p>Guidelines from both Kidney Disease Outcome Quality Initiative (KDOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) suggest that bone biopsy may be useful to guide management decisions in children with stage G5 disease who have one or more of the following findings: persistent bone pain, nontraumatic fractures, or continued abnormal laboratory findings despite adequate routine therapeutic interventions. </p><p class="headingAnchor" id="H11"><span class="h1">SCREENING/MONITORING FOR CKD-MBD</span><span class="headingEndMark"> — </span>Early detection of bone metabolic abnormalities ensures that therapeutic interventions can be initiated, thereby preventing or minimizing secondary hyperparathyroidism and its consequent effect on bone disease. Screening/monitoring of serum concentrations of calcium, phosphate, alkaline phosphatase (ALP), and parathyroid hormone (PTH) in all children with CKD should begin at CKD stage G2  (<a class="graphic graphic_figure graphicRef107125" href="/d/graphic/107125.html" rel="external">figure 1</a>) [<a href="#rid26">26,27</a>].</p><p class="headingAnchor" id="H3634271636"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>At our center, we begin to monitor serum calcium, phosphorus, PTH, total ALP, and 25-hydroxyvitamin D starting at CKD stage G2 with a schedule that is consistent with the Kidney Disease Outcome Quality Initiative (KDOQI) guidelines and the European Society for Paediatric Nephrology and the CKD-MBD working group of the European Renal Association–European Dialysis and Transplant Association [<a href="#rid1">1,3,28</a>]. If therapy is initiated to correct serum abnormalities or to treat renal osteodystrophy, the guidelines recommend that laboratory evaluation should be performed more frequently to ensure a response to therapy or to identify the need to adjust therapy [<a href="#rid25">25</a>]:</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Calcium and phosphate measurements</strong>:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Stage G2 – Measurements at least yearly</p><p class="bulletIndent3"><span class="glyph">-</span>Stage G3 – Measurements at least every six months</p><p class="bulletIndent3"><span class="glyph">-</span>Stage G4 – Measurements at least every three months</p><p class="bulletIndent3"><span class="glyph">-</span>Stage G5 – Measurements at least monthly</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PTH and ALP measurements</strong>:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Stage G2 – Measurements at least yearly</p><p class="bulletIndent3"><span class="glyph">-</span>Stage G3 – Measurements at least every six months</p><p class="bulletIndent3"><span class="glyph">-</span>Stages G4 and 5 – Measurements at least every three months</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Serum 25-hydroxyvitamin D</strong> concentrations are measured yearly for children with CKD stages 2 to 4 (glomerular filtration rate [GFR] of 15 to 89 mL/min per 1.73 m<sup>2</sup>) with serum PTH values above the target range for the stage of CKD [<a href="#rid1">1,27,29</a>]. In our practice, if vitamin D therapy is initiated, serum 25-hydroxyvitamin D is measured every three months until normal serum 25-hydroxyvitamin D levels are achieved and then yearly afterwards. </p><p></p><p>We do not perform radiological assessment or measure 1,25-dihyroxyvitamin D or bone turnover markers, such as bone-specific ALP, osteocalcin, or C-telopeptide, on a routine basis. </p><p class="headingAnchor" id="H1199892765"><span class="h2">Alternative screening protocols</span><span class="headingEndMark"> — </span>Other guidelines have been published regarding monitoring for pediatric CKD-MBD, including: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney Disease: Improving Global Outcomes (KDIGO) guidelines</strong> recommend monitoring of serum levels of calcium, phosphate, PTH, and ALP beginning in children with stage G2 disease; however, there is no information on the type and frequency of testing for children with stage G2 disease. There is specific information for monitoring in children with more advanced disease [<a href="#rid3">3</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monitoring of calcium and phosphate measurements:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Stage G3 – Measurements at least every 6 to 12 months</p><p class="bulletIndent3"><span class="glyph">-</span>Stage G4 – Measurements at least every 3 to 6 months</p><p class="bulletIndent3"><span class="glyph">-</span>Stage G5 – Measurements at least every 1 to 3 months</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monitoring PTH measurements:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Stage G3 – Measurements are based on the baseline level and CKD progression</p><p class="bulletIndent3"><span class="glyph">-</span>Stage G4 – Measurements at least every 6 to 12 months</p><p class="bulletIndent3"><span class="glyph">-</span>Stage G5 – Measurements at least every 3 to 6 months</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ALP is measured for patients with CKD stage G4 and G5 every 12 months or more frequently when PTH is elevated.</p><p></p><p class="bulletIndent1">The guidelines suggest it is reasonable to increase the frequency of measurements for children who are being treated for CKD-MBD to monitor for efficacy and side effects or who have identified biochemical abnormalities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <strong>European Paediatric Dialysis Working Group</strong> (EPDWG) guidelines recommend obtaining calcium, phosphorus, PTH, and ALP based on GFR as follows [<a href="#rid30">30</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stage 3 (GFR 30 to 59 mL/min/1.73m<sup>2</sup>) – Measurement at least every six months</p><p class="bulletIndent2"><span class="glyph">•</span>Stage 4 (GFR 15 to 29 mL/min/1.73m<sup>2</sup>) – Measurement at least every three months</p><p class="bulletIndent2"><span class="glyph">•</span>Stage 5 (GFR &lt;15 mL/min/1.73m<sup>2</sup>, or on dialysis) – Measurement at least monthly</p><p></p><p class="bulletIndent1">In addition, subsequent ESPN CKD-MBD and Dialysis WG guidelines recommend serum 25-hydroxyvitamin D levels be obtained every 6 to 12 months in children with CKD stages 2 to 5 who are not on vitamin D therapy [<a href="#rid31">31</a>]. For those who receive vitamin D therapy, it is recommended that serum 25-hydroxyvitamin D be measured three months after initiation of vitamin D therapy. If the serum 25-hydroxyvitamin D level is normal, levels should be measured every six months. If low, replacement therapy should be provided with a repeat 25-hydroxyvitamin D level obtained in three months.</p><p></p><p class="headingAnchor" id="H997084816"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H3337250362"><span class="h2">Goals and approach</span><span class="headingEndMark"> — </span>The goals of therapy are to prevent and treat secondary hyperparathyroidism, which results in bone disease (osteitis fibrosa cystica and mixed osteodystrophy) while avoiding the development of adynamic bone disease or osteomalacia from too aggressive therapy (see <a class="local">'Bone pathology'</a> above). Secondary hyperparathyroidism is due to hyperplasia of the parathyroid glands caused by phosphate retention, 1,25 dihydroxy-vitamin D deficiency, hypocalcemia, and skeletal resistance to parathyroid hormone (PTH) action (see <a class="local">'Phosphate retention and secondary hyperparathyroidism'</a> above and  <a class="medical medical_review" href="/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Abnormalities of parathyroid hormone, calcium, phosphorus, fibroblast growth factor 23, and vitamin D metabolism'</a>). </p><p>The management and prevention of secondary hyperparathyroidism involves:</p><p class="bulletIndent1"><span class="glyph">●</span>Correction of phosphate retention by dietary phosphate restriction, usually in combination with a calcium-containing phosphate binder. (See <a class="local">'Retention of phosphate and hyperphosphatemia'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In children with stages G2 to G4 disease  (<a class="graphic graphic_table graphicRef89808" href="/d/graphic/89808.html" rel="external">table 1</a>), assess and replenish 25-hydroxyvitamin D (if the level is low) with oral <a class="drug drug_pediatric" data-topicid="13274" href="/d/drug information/13274.html" rel="external">ergocalciferol</a> or <a class="drug drug_pediatric" data-topicid="13086" href="/d/drug information/13086.html" rel="external">cholecalciferol</a> and maintain adequate calcium levels. For children with normal 25-hydroxyvitamin D levels and elevated PTH, an active vitamin D analogue (eg, <a class="drug drug_pediatric" data-topicid="13107" href="/d/drug information/13107.html" rel="external">calcitriol</a>) is provided in place of ergocalciferol or cholecalciferol. (See <a class="local">'Vitamin D deficiency'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In children with stage G5 disease, the combination of dietary phosphate restriction, phosphate binders, and an active vitamin D analogue is generally required to maintain a normal age-appropriate serum phosphate value and a serum PTH concentration that is no more than two to three times normal.</p><p></p><p>The following discussion regarding the specific interventions involved in the management of bone metabolism in children with CKD is consistent with guidelines from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.kidney.org%2Fprofessionals%2Fguidelines&amp;token=mwx%2FWFqfIsxpjED21OsijeC6nVb9OOdf2ctFKSDhUkeo7woDHDqqTAFuB14mPyNw1FjMB29uSsN6BBA179a0fw%3D%3D&amp;TOPIC_ID=6092" target="_blank">Kidney Disease Outcome Quality Initiative (KDOQI)</a>, Kidney Disease: Improving Global Outcomes (KDIGO), and the European Society of Paediatric Nephrology (ESPN) CKD-MBD and Dialysis Working Group (ESPN CKD-MBD and Dialysis WG) [<a href="#rid1">1,3,31</a>].</p><p class="headingAnchor" id="H217482676"><span class="h3">PTH target goals</span><span class="headingEndMark"> — </span>The serum parathyroid hormone (PTH) concentration is inversely correlated with kidney function and is almost always elevated when the glomerular filtration rate (GFR) falls below 60 mL/min per 1.73 m<sup>2</sup> [<a href="#rid21">21</a>]. The optimal serum PTH values in children with CKD is uncertain as a result of the insufficient upon which to generate definitive recommendations. Most experts including the authors follow the recommendations of the European CKD-MBD and Dialysis WG that the PTH should be maintained at a near normal level in children with Stage 2 to 5 CKD and at two to three times the upper limit of normal for those on dialysis [<a href="#rid30">30,32</a>]. Additional recommendations that exist have been published by KDOQI and KDIGO.</p><p class="bulletIndent1"><span class="glyph">●</span>The KDOQI guidelines recommend targeted levels of serum intact PTH at different stages of CKD as follows [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stages G2 and G3 – 35 to 70 pg/mL</p><p class="bulletIndent2"><span class="glyph">•</span>Stage G4 – 70 to 110 pg/mL</p><p class="bulletIndent2"><span class="glyph">•</span>Stage G5 – 200 to 300 pg/mL</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The KDIGO guidelines suggest [<a href="#rid3">3</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients on dialysis, PTH levels are maintained in the range of approximately two to nine times the upper normal limit.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with CKD not on dialysis, if PTH is progressively rising or is persistently above the upper limit of normal, the cause for the elevated value should be evaluated for modifiable factors, including hyperphosphatemia, hypocalcemia, high phosphate intake, and vitamin D deficiency.</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Retention of phosphate and hyperphosphatemia</span><span class="headingEndMark"> — </span>Phosphate is a salt of oxidized phosphoric acid and is a key component of bone matrix. As noted above, phosphate retention begins with the decline in GFR resulting in hyperphosphatemia when GFR falls below 30 mL/min per 1.73 m<sup>2</sup> (CKD G4 to G5 disease). Management is directed at preventing hyperphosphatemia and phosphate retention because of their critical role in the development of secondary hyperparathyroidism and vascular injury. (See <a class="local">'Phosphate retention and secondary hyperparathyroidism'</a> above and  <a class="medical medical_review" href="/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Phosphate retention and hyperphosphatemia'</a>.)</p><p class="headingAnchor" id="H3271652807"><span class="h3">Normal phosphate levels</span><span class="headingEndMark"> — </span>Normally, the serum phosphorus concentration is highest in infants less than three months of age. As the child ages, the normal range of phosphorus values decreases:</p><p class="bulletIndent1"><span class="glyph">●</span>0 to 3 months of age – 4.8 to 7.4 mg/dL (1.55 to 2.39 mmol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>1 to 5 years of age – 4.5 to 6.5 mg/dL (1.45 to 2.1 mmol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>6 to 12 years of age – 3.6 to 5.8 mg/dL (1.16 to 1.87 mmol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>13 to 20 years of age – 2.3 to 4.5 mg/dL (0.74 to 1.45 mmol/L)</p><p></p><p class="headingAnchor" id="H13"><span class="h3">Goals</span><span class="headingEndMark"> — </span>In our center, and in accordance with the KDOQI Pediatric Nutrition guidelines and the recommendations from the Pediatric Renal Nutrition Taskforce and the European CKD-MBD and Dialysis WG, we target age-appropriate normal serum phosphate levels. This is in contrast to the slightly elevated levels recommended for patients with Stage G5 CKD in the KDOQI Pediatric Bone guidelines [<a href="#rid1">1</a>].</p><p>Pediatric Renal Nutrition Taskforce and the European CKD-MBD and Dialysis WG provide guidance for the dietary intake of calcium and phosphorus in children with CKD stages 2 to 5 and on dialysis (CKD 2 to 5D). They provide information on the common calcium- and phosphorus-containing foods, the assessment of dietary calcium and phosphorus intake, requirements for calcium and phosphorus in healthy children and necessary modifications for children with CKD 2 to 5D, and the dietary management of hypo- and hypercalcemia and hyperphosphatemia [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H14"><span class="h3">Interventions</span><span class="headingEndMark"> — </span>In children with CKD, the two therapeutic interventions used to attain and maintain the targeted serum phosphate goal are dietary phosphorus restriction followed by the use of phosphate binders.</p><p class="headingAnchor" id="H39327940"><span class="h4">Dietary restriction</span><span class="headingEndMark"> — </span>In controlled studies of both children and adults, dietary phosphate restriction results in decreased serum PTH level and increased serum 1,25-dihydroxyvitamin D concentrations [<a href="#rid33">33,34</a>] (see  <a class="medical medical_review" href="/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease"</a>). Conversely, an intake of phosphate that is twice the Dietary Reference Intake (DRI) in children with CKD stage G3 increases serum PTH and decreases serum 1,25-dihydroxyvitamin D [<a href="#rid33">33</a>]. </p><p>For children with CKD stages G3 to G5 and normal phosphate levels, dietary phosphate restriction is based on age and serum PTH levels and phosphate concentrations. </p><p class="bulletIndent1"><span class="glyph">●</span>If the serum PTH is above the target range and the serum phosphate concentration is normal, dietary phosphate is restricted to 100 percent of the DRI for age [<a href="#rid29">29</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>0 to 0.5 years – 100 mg/day</p><p class="bulletIndent2"><span class="glyph">•</span>0.5 to 1 year – 275 mg/day</p><p class="bulletIndent2"><span class="glyph">•</span>1 to 3 years – 460 mg/day</p><p class="bulletIndent2"><span class="glyph">•</span>4 to 8 years – 500 mg/day</p><p class="bulletIndent2"><span class="glyph">•</span>9 to 19 years – 1250 mg/day</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the serum PTH is above the target range and the serum phosphate concentration is above the age-appropriate normal range, dietary phosphate is restricted to 80 percent of the DRI for age [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>0 to 0.5 years – 80 mg/day</p><p class="bulletIndent2"><span class="glyph">•</span>0.5 to 1 year – 220 mg/day</p><p class="bulletIndent2"><span class="glyph">•</span>1 to 3 years – 368 mg/day</p><p class="bulletIndent2"><span class="glyph">•</span>4 to 8 years – 400 mg/day</p><p class="bulletIndent2"><span class="glyph">•</span>9 to 19 years – 1000 mg/day</p><p></p><p>After the initiation of dietary restriction, serum phosphate should be monitored at least every three months in children with CKD stages G3 and G4 and monthly in those with CKD stage G5. Studies in children with CKD report no association of dietary phosphate restriction with poor linear growth [<a href="#rid35">35-38</a>]. However, serum phosphate concentrations below the target range for age should be avoided because of the potential adverse effects of hypophosphatemia on linear growth and bone mineralization.</p><p class="headingAnchor" id="H39327947"><span class="h4">Phosphate binders</span><span class="headingEndMark"> — </span>Compliance with dietary phosphate restriction in children is poor, as most of their favorite foods are rich in phosphate. Thus, despite attempts to restrict phosphate intake, phosphate binders often become necessary to prevent phosphate absorption from the gastrointestinal tract. Phosphate binders are typically prescribed if the follow-up serum phosphate is above the target goal following institution of dietary restriction.</p><p class="headingAnchor" id="H2356524660"><span class="h5">Choice of binders</span><span class="headingEndMark"> — </span>In children, several observational studies have shown that calcium-based phosphate binders are effective and safe in lowering serum phosphate and PTH levels [<a href="#rid39">39-41</a>]. These agents are recommended as the initial phosphate binder in children with CKD because other agents have significant side effects (such as aluminum [<a href="#rid42">42</a>]) or have shown no increased benefit regarding calcium, phosphate, or PTH levels (such as <a class="drug drug_pediatric" data-topicid="12975" href="/d/drug information/12975.html" rel="external">sevelamer</a>) [<a href="#rid1">1,3,43</a>]. The choice among the many different calcium-containing phosphate binders, such as <a class="drug drug_pediatric" data-topicid="12569" href="/d/drug information/12569.html" rel="external">calcium carbonate</a>, <a class="drug drug_pediatric" data-topicid="13085" href="/d/drug information/13085.html" rel="external">calcium acetate</a>, <a class="drug drug_pediatric" data-topicid="12956" href="/d/drug information/12956.html" rel="external">calcium gluconate</a>, and calcium ketoglutarate, is in large part dependent upon the patient's tolerance of the binder and the choice of the clinician. Several studies in adults have not shown an overall advantage of one preparation over another [<a href="#rid1">1</a>]. The total dose of elemental calcium should not exceed twice the DRI for calcium based on age with a maximum of 2500 mg/day, including the dietary calcium intake.(See  <a class="medical medical_review" href="/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease", section on 'Phosphate binders'</a>.)</p><p>However, calcium-based phosphate binders should not be used as the sole agent in patients who are hypercalcemic due to concerns of soft tissue calcifications (serum calcium &gt;10.2 mg/dL [2.55 mmol/L]). In this setting, non-calcium binders, such as <a class="drug drug_pediatric" data-topicid="12975" href="/d/drug information/12975.html" rel="external">sevelamer</a>, are preferred [<a href="#rid44">44</a>]. In children, open-label studies have shown that sevelamer carbonate lowers serum phosphate better than placebo and is as effective as <a class="drug drug_pediatric" data-topicid="13085" href="/d/drug information/13085.html" rel="external">calcium acetate</a> without serious adverse effects [<a href="#rid45">45,46</a>]. Sevelamer carbonate is also associated with an improvement in serum bicarbonate levels, such that <a class="drug drug_pediatric" data-topicid="12795" href="/d/drug information/12795.html" rel="external">sodium bicarbonate</a> therapy could be discontinued. (See  <a class="medical medical_review" href="/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease", section on 'Phosphate binders'</a>.)</p><p>The following phosphate binders should <strong>not</strong> be used in children with CKD:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13169" href="/d/drug information/13169.html" rel="external">Aluminum hydroxide</a> because of aluminum bone toxicity [<a href="#rid42">42</a>]. Aluminum deposition can cause low bone turnover, leading to renal osteodystrophy (eg, adynamic bone disease and osteomalacia). Aluminum usage can also be associated with neurocognitive and hematologic complications. (See  <a class="medical medical_review" href="/d/html/1839.html" rel="external">"Aluminum toxicity in chronic kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Magnesium-containing antacids</strong> (such as <a class="drug drug_pediatric" data-topicid="12980" href="/d/drug information/12980.html" rel="external">magnesium hydroxide</a>) because of the risk of hypermagnesemia and the frequent development of diarrhea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12867" href="/d/drug information/12867.html" rel="external">Calcium citrate</a> because it markedly increases the absorption of dietary aluminum.</p><p></p><p class="headingAnchor" id="H1225253380"><span class="h5">Administration</span><span class="headingEndMark"> — </span>Phosphate binders should be taken 10 to 15 minutes before or during the meal. The beneficial effect is less when taken between meals, since most dietary phosphate has already been absorbed.</p><p>Phosphate binders, regardless of the agent used, have a limited phosphate-binding capacity. As examples, 1 g of <a class="drug drug_pediatric" data-topicid="12569" href="/d/drug information/12569.html" rel="external">calcium carbonate</a> binds 39 mg of phosphate, 1 g of <a class="drug drug_pediatric" data-topicid="13085" href="/d/drug information/13085.html" rel="external">calcium acetate</a> binds 45 mg of phosphate, and 400 mg of <a class="drug drug_pediatric" data-topicid="12975" href="/d/drug information/12975.html" rel="external">sevelamer</a> HCl binds 32 mg of phosphate. Thus, phosphate-binding compounds will be effective in lowering serum phosphate levels only if dietary phosphate restriction is continued.</p><p class="headingAnchor" id="H15"><span class="h2">Vitamin D deficiency</span></p><p class="headingAnchor" id="H1517113951"><span class="h3">Overview</span><span class="headingEndMark"> — </span>In children with CKD, the production of 1,25-dihydroxyvitamin D is impaired due to phosphate retention, low serum 25-hydroxyvitamin D, and increased serum FGF23 [<a href="#rid26">26,47</a>]. Phosphate retention and 1,25-dihydroxyvitamin D deficiency decrease serum calcium, which contribute directly to secondary hyperparathyroidism and renal osteodystrophy. As a result, vitamin D supplementation is usually required and the choice of formulation is based on clinical settings. (See  <a class="medical medical_review" href="/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a> and <a class="local">'Persistent hyperparathyroidism'</a> below.)</p><p>In our center, initial treatment is focused on replenishing inadequate stores of 25-hydroxyvitamin D with vitamin D analogues such as <a class="drug drug_pediatric" data-topicid="13274" href="/d/drug information/13274.html" rel="external">ergocalciferol</a> or <a class="drug drug_pediatric" data-topicid="13086" href="/d/drug information/13086.html" rel="external">cholecalciferol</a> in children with stages G2 to G4 disease as needed. Active vitamin D analogues (eg, <a class="drug drug_pediatric" data-topicid="13107" href="/d/drug information/13107.html" rel="external">calcitriol</a>) are provided to children with stage G5 disease with an elevated PTH and children with stage G2 to G4 disease, normal 25-hydroxyvitamin D level, and persistent elevation of PTH.</p><p class="headingAnchor" id="H3100280681"><span class="h3">CKD stages G2 to G4</span><span class="headingEndMark"> — </span>Management is dependent on the concentration of 25-hydroxyvitamin D.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated PTH and</strong> <strong>25-OH vitamin D deficiency</strong> – Deficiency of 25-hydroxyvitamin D is common in children with CKD [<a href="#rid48">48-51</a>]. Additional risk factors for vitamin D deficiency include older age, darker skin pigmentation, higher body mass index, lower daily milk intake, more advanced CKD, and no vitamin D supplementation [<a href="#rid52">52</a>]. For children with 25-hydroxyvitamin D deficiency, <a class="drug drug_pediatric" data-topicid="13274" href="/d/drug information/13274.html" rel="external">ergocalciferol</a> or <a class="drug drug_pediatric" data-topicid="13086" href="/d/drug information/13086.html" rel="external">cholecalciferol</a> is provided when the serum 25-hydroxyvitamin D is &lt;30 ng/mL (&lt;75 nmol/L), which concurs with the major society guidelines [<a href="#rid1">1,29,31</a>]. </p><p></p><p class="bulletIndent1">Although KDOQI recommends <a class="drug drug_pediatric" data-topicid="13274" href="/d/drug information/13274.html" rel="external">ergocalciferol</a>, there is no difference in efficacy between ergocalciferol and <a class="drug drug_pediatric" data-topicid="13086" href="/d/drug information/13086.html" rel="external">cholecalciferol</a>. Ergocalciferol is available as an <strong>8000 units/mL preparation</strong>, which is helpful when using high doses in small children. We follow the KDOQI guidelines for the dose of vitamin D supplementation, which depends on serum 25-hydroxyvitamin D levels as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vitamin D insufficiency, 16 to 30 ng/mL – 2000 international units/day for three months or 50,000 international units every month for three months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vitamin D deficiency, 5 to 15 ng/mL – 4000 international units/day for three months or 50,000 international units every other week for three months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe vitamin D deficiency, &lt;5 ng/mL – 8000 international units/day for four weeks then 4000 international units/day for two months for total therapy of three months. Alternatively, 50,000 international units/week for four weeks followed by 50,000 international units two times/month for a total therapy of three months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated PTH and normal 25-OH vitamin</strong> <strong>D</strong> – Levels of 1,25-dihydroxyvitamin D (<a class="drug drug_pediatric" data-topicid="13107" href="/d/drug information/13107.html" rel="external">calcitriol</a>) usually fall below normal when the glomerular filtration is &lt;60 mL/min/1.73 m<sup>2</sup>. In this setting, an active vitamin D analogue (eg, calcitriol) is provided. Calcitriol is our preferred initial choice of active vitamin D therapy [<a href="#rid53">53</a>]. In children, calcitriol has been reported in observational studies to decrease serum PTH concentrations and improve the linear growth of children with CKD [<a href="#rid54">54,55</a>]. (See  <a class="medical medical_review" href="/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Decreased calcitriol activity'</a>.)</p><p></p><p class="bulletIndent1">Active vitamin D analogue (eg, <a class="drug drug_pediatric" data-topicid="13107" href="/d/drug information/13107.html" rel="external">calcitriol</a>) is provided <strong>if all</strong> of the following criteria are met:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum 25-hydroxyvitamin D is &gt;30 ng/mL (&gt;75 nmol/L)</p><p class="bulletIndent2"><span class="glyph">•</span>Serum PTH is above the target range</p><p class="bulletIndent2"><span class="glyph">•</span>Serum calcium level is &lt;10.2 mg/dL (&lt;2.37 mmol/L) [<a href="#rid52">52</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Serum phosphate level is less than the age-appropriate upper limits for the stage of CKD</p><p></p><p class="bulletIndent1">Once active vitamin D therapy is started, serum calcium and phosphate concentrations should be measured after one month of therapy and every three months thereafter. Serum PTH should be measured at least every three months. The dose of <a class="drug drug_pediatric" data-topicid="13107" href="/d/drug information/13107.html" rel="external">calcitriol</a> should be modified or held if hypercalcemia develops or the serum PTH falls below the target range for the stage of CKD. If hyperphosphatemia develops or persists, the dose should be decreased and phosphate binder usage and dietary phosphate restriction intensified.</p><p></p><p class="headingAnchor" id="H3180536346"><span class="h3">CKD stage 5</span><span class="headingEndMark"> — </span>In children with CKD stage G5 (GFR &lt;15 mL/min per 1.7<sup>3</sup> m<sup>2</sup>) and serum PTH &gt;300 pg/mL, <a class="drug drug_pediatric" data-topicid="13107" href="/d/drug information/13107.html" rel="external">calcitriol</a> should be administered to reduce the serum PTH. Although the optimal PTH target remains controversial, we generally target a PTH value that is two to three times the upper limit of normal in accordance with the recommendations of the European CKD-MBD and Dialysis WG and similar to the 100 to 300 pg/mL recommendation based on data from peritoneal dialysis patients in the International Pediatric Peritoneal Dialysis Network Registry [<a href="#rid1">1,56-58</a>].</p><p class="bulletIndent1">In these patients, serum PTH should be measured monthly for three months and then at least every three months. Serum PTH concentrations &lt;100 ng/L should be avoided to prevent adynamic bone disease.</p><p></p><p class="headingAnchor" id="H3881573327"><span class="h3">Calcitriol</span><span class="headingEndMark"> — </span>The recommended starting dose for <a class="drug drug_pediatric" data-topicid="13107" href="/d/drug information/13107.html" rel="external">calcitriol</a> is based on the body weight of the child:</p><p class="bulletIndent1"><span class="glyph">●</span>Weight &lt;10 kg – 0.05 mcg every other day</p><p class="bulletIndent1"><span class="glyph">●</span>Weight between 10 kg and 20 kg – 0.1 mcg to 0.15 mcg per day</p><p class="bulletIndent1"><span class="glyph">●</span>Weight &gt;20 kg – 0.25 mcg per day</p><p></p><p>Dosing of <a class="drug drug_pediatric" data-topicid="13107" href="/d/drug information/13107.html" rel="external">calcitriol</a> should be adjusted based on subsequent laboratory results.</p><p>The use of <a class="drug drug_pediatric" data-topicid="13107" href="/d/drug information/13107.html" rel="external">calcitriol</a> in patients with an elevation of serum calcium or phosphate can lead to soft tissue calcification due to an increase in the calcium phosphate product. The increased gastrointestinal absorption of calcium and phosphate that occurs with calcitriol usage can also contribute to soft tissue calcification. (See <a class="local">'Complications'</a> above and  <a class="medical medical_review" href="/d/html/7222.html" rel="external">"Vascular calcification in chronic kidney disease", section on 'Risk factors'</a>.)</p><p>More selective vitamin D analogues, such as <a class="drug drug_general" data-topicid="16467" href="/d/drug information/16467.html" rel="external">alfacalcidol</a>, <a class="drug drug_pediatric" data-topicid="13032" href="/d/drug information/13032.html" rel="external">paricalcitol</a> [<a href="#rid59">59,60</a>], or <a class="drug drug_general" data-topicid="8651" href="/d/drug information/8651.html" rel="external">doxercalciferol</a>, have been developed to reduce the risk of hypercalcemia and hyperphosphatemia. Limited pediatric data have shown that these agents are effective in lowering PTH levels [<a href="#rid60">60,61</a>], and there is no convincing evidence supporting the use of one specific vitamin D analogue over another. These analogues are most often used in children who have developed elevated serum calcium levels associated with <a class="drug drug_pediatric" data-topicid="13107" href="/d/drug information/13107.html" rel="external">calcitriol</a> therapy. These agents should be started at the lowest possible dose and be titrated based on trends of serum calcium, phosphate, and PTH levels to achieve target PTH concentrations and maintain a normal serum calcium level. </p><p class="headingAnchor" id="H18"><span class="h2">Calcium</span><span class="headingEndMark"> — </span>The total serum calcium should be maintained within the age-appropriate normal range, generally between 8.8 and 9.7 mg/dL (2.2 to 2.37 mmol/L) based on the laboratory that is used [<a href="#rid3">3</a>]. </p><p class="headingAnchor" id="H19"><span class="h3">Hypocalcemia</span><span class="headingEndMark"> — </span>If appropriate therapy is not provided, hypocalcemia can result due to progressive loss of kidney function resulting in phosphate retention and 1,25-dihydroxyvitamin D deficiency. Symptomatic hypocalcemia should initially be treated with parenteral <a class="drug drug_pediatric" data-topicid="12651" href="/d/drug information/12651.html" rel="external">calcium chloride</a> [<a href="#rid1">1</a>]. Long-term therapy requires appropriate management of hyperphosphatemia and vitamin D deficiency, as described above, and sufficient dietary calcium. For children with CKD stages G2 to G5, the 2008 KDOQI pediatric nutrition guidelines suggest that the total calcium intake (nutritional sources and phosphate binders) be in the range of 100 to 200 percent of the DRI for age  (<a class="graphic graphic_table graphicRef52366" href="/d/graphic/52366.html" rel="external">table 3</a>) [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/d/html/826.html" rel="external">"Treatment of hypocalcemia"</a>.)</p><p class="headingAnchor" id="H20"><span class="h3">Hypercalcemia</span><span class="headingEndMark"> — </span>Children with CKD who are treated with vitamin D therapy and calcium-containing phosphate binders may develop hypercalcemia. If the total serum calcium value exceeds 10.2 mg/dL (2.55 mmol/L), the dose of calcium-based phosphate binders should be reduced and/or therapy changed to <a class="drug drug_pediatric" data-topicid="12975" href="/d/drug information/12975.html" rel="external">sevelamer</a> and the use of calcium supplementation stopped [<a href="#rid19">19</a>]. Vitamin D therapy should also be discontinued until the serum calcium returns to the target range and then restarted with an appropriate dose adjustment.</p><p class="headingAnchor" id="H21"><span class="h2">Persistent hyperparathyroidism</span><span class="headingEndMark"> — </span>In children who continue to have persistent hyperparathyroidism despite being vitamin D replete and being compliant with their dietary phosphate restriction, phosphate binders and vitamin D analogue therapy; calcimimetic therapy should be considered. On rare occasions, parathyroidectomy may be indicated if all conventional therapy fails and/or when secondary hyperparathyroidism transitions into a tertiary hyperparathyroidism.</p><p class="headingAnchor" id="H4091948163"><span class="h3">Calcimimetics</span><span class="headingEndMark"> — </span>Calcimimetics (eg, <a class="drug drug_pediatric" data-topicid="122817" href="/d/drug information/122817.html" rel="external">cinacalcet</a>) are being increasingly used to suppress PTH secretion and decrease the risk of hypercalcemia associated with <a class="drug drug_pediatric" data-topicid="13107" href="/d/drug information/13107.html" rel="external">calcitriol</a>. These agents, which increase the sensitivity of the calcium-sensing receptor (CaSR) in the parathyroid gland to calcium, have undergone limited study in the pediatric population. The available data suggest that the use of calcimimetics in children with severe and/or refractory hyperparathyroidism is effective in reducing PTH levels [<a href="#rid62">62-67</a>]. The European Society for Pediatric Nephrology, Chronic Kidney Disease-Mineral and Bone Disorder and Dialysis Working Groups, and the ERA-EDTA has published a position statement for the use of cinacalcet in children on dialysis in whom secondary hyperparathyroidism is not adequately controlled with standard therapy [<a href="#rid68">68</a>]. However, additional information is needed to ensure its safety, particularly, the risk of hypocalcemia, as well as efficacy.(See  <a class="medical medical_review" href="/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis", section on 'Calcimimetics'</a>.)</p><p class="headingAnchor" id="H3919958183"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110751.html" rel="external">"Society guideline links: Chronic kidney disease in children"</a> and  <a class="medical medical_society_guidelines" href="/d/html/112930.html" rel="external">"Society guideline links: Chronic kidney disease-mineral and bone disorder"</a>.)</p><p class="headingAnchor" id="H248866175"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/86001.html" rel="external">"Patient education: Bone problems caused by kidney disease (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction and definition</strong> ‒ In children with chronic kidney disease (CKD), abnormalities in mineral bone metabolism occur early and are universal. If untreated, these patients will develop CKD-mineral and bone disorder (CKD-MBD). Both in children and adults, CKD-MBD is defined as one or a combination of the following three components:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abnormalities of calcium, phosphorus, parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and vitamin D metabolism</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abnormalities in bone turnover, mineralization, volume linear growth, or strength</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Extraskeletal calcification</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> ‒ Clinical manifestations of CKD-MBD vary based on the severity of CKD  (<a class="graphic graphic_table graphicRef89808" href="/d/graphic/89808.html" rel="external">table 1</a>) and whether interventions to prevent MBD have been instituted. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CKD-MBD is first be detected in children with stage G2 CKD based on abnormal laboratory levels of serum calcium, phosphorus, PTH, and 1,25 dihydroxyvitamin D. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Untreated patients with more severe CKD (stages G3 through G5) become increasingly symptomatic with bone pain, difficulty in walking, and/or skeletal deformities such as varus and valgus deformities of the long bones. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone pathology</strong> <strong>‒ </strong>Renal osteodystrophy, one of the components of CKD-MBD, is defined as alterations in bone morphology associated with CKD based upon bone biopsy. It includes several different pathologic forms (osteitis fibrosa cystica, adynamic bone disease, osteomalacia, and mixed osteodystrophy). (See <a class="local">'Bone pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> ‒ The diagnosis of pediatric CKD-MBD is made upon fulfilling one of the criteria for the definition of CKD-MBD. This typically occurs when a laboratory abnormality (eg, calcium, phosphorus, or PTH) is detected during ongoing screening/monitoring of children with CKD stages G2 through G4. Bone biopsy is rarely performed clinically, but can confirm the diagnosis when there are changes consistent with renal osteodystrophy (ie, abnormalities of bone turnover and mineralization). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening and monitoring</strong> ‒ Screening and monitoring of serum concentrations of calcium, phosphate, PTH and total alkaline phosphatase (ALP) should occur in all children with CKD beginning at CKD stage G2. For children with elevated PTH levels, serum hydroxyvitamin D concentrations are measured yearly. (See <a class="local">'Screening/monitoring for CKD-MBD'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management goals</strong> ‒ The goals of therapy are to prevent and treat secondary hyperparathyroidism, which results in bone disease (osteitis fibrosa cystica and mixed osteodystrophy) while avoiding the development of adynamic bone disease or osteomalacia from too aggressive therapy. Although data are insufficient to determine with certainty optimal PTH target goals for children with CKD, we target PTH levels for near normal levels for children with stage 2 to 5 CKD and two to three times the upper limit of normal for those on dialysis as recommended by the European CKD-MBD and Dialysis working group. (See <a class="local">'Goals and approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management approach</strong> ‒ Prevention and treatment of secondary hyperparathyroidism include the following: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prevention of phosphate retention and hyperphosphatemia</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Dietary restriction is the initial intervention. The degree of daily dietary phosphate is based on the age of the child and serum PTH and phosphate concentration. (See <a class="local">'Dietary restriction'</a> above.)</p><p></p><p class="bulletIndent3">For patients in whom dietary restriction is not sufficient, we suggest the administration of calcium-based phosphate binders such as <a class="drug drug_pediatric" data-topicid="12569" href="/d/drug information/12569.html" rel="external">calcium carbonate</a>, <a class="drug drug_pediatric" data-topicid="13085" href="/d/drug information/13085.html" rel="external">calcium acetate</a>, <a class="drug drug_pediatric" data-topicid="12956" href="/d/drug information/12956.html" rel="external">calcium gluconate</a>, and calcium ketoglutarate (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The choice of phosphate binder is dependent upon the patient's tolerance of the binder and the preference of the clinician. For patients who are hypercalcemic, the preferred agent is <a class="drug drug_pediatric" data-topicid="12975" href="/d/drug information/12975.html" rel="external">sevelamer</a>. Significant adverse effects are associated with <a class="drug drug_pediatric" data-topicid="12867" href="/d/drug information/12867.html" rel="external">calcium citrate</a>, <a class="drug drug_pediatric" data-topicid="13169" href="/d/drug information/13169.html" rel="external">aluminum hydroxide</a>, and magnesium-containing antacids, and these agents should <strong>not </strong>be used in children with CKD. (See <a class="local">'Phosphate binders'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Provision of adequate vitamin D therapy</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In children with CKD stages G2 to G4 with an elevated PTH level and a 25-hydroxyvitamin D level is &lt;30 ng/mL (&lt;75 nmol/L), we suggest that <a class="drug drug_pediatric" data-topicid="13274" href="/d/drug information/13274.html" rel="external">ergocalciferol</a> or <a class="drug drug_pediatric" data-topicid="13086" href="/d/drug information/13086.html" rel="external">cholecalciferol</a> be given (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'CKD stages G2 to G4'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In children with CKD stages G2 to G4 with an elevated PTH level and a 25-hydroxyvitamin D level &gt;30 ng/mL (&gt;75 nmol/L) and the serum calcium level is &lt;10.2 mg/dL (2.37 mmol/L), we suggest <a class="drug drug_pediatric" data-topicid="13107" href="/d/drug information/13107.html" rel="external">calcitriol</a> therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'CKD stages G2 to G4'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In children with CKD stage 5 and elevated PTH levels, we suggest that <a class="drug drug_pediatric" data-topicid="13107" href="/d/drug information/13107.html" rel="external">calcitriol</a> should be administered until serum PTH is reduced to a range between two to three times the upper limit of normal (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, the optimal target PTH range remains controversial. (See <a class="local">'CKD stage 5'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maintenance of normal calcium</strong> ‒ Serum calcium should be maintained within an age-appropriate normal range for the laboratory used, generally between 8.8 and 9.7 mg/dL (2.2 to 2.37 mmol/L). If the patient is hypocalcemic, calcium supplementation is provided. (See <a class="local">'Hypocalcemia'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 2005; 46:S1.</a></li><li><a class="nounderline abstract_t">KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3:136.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2017; 7:1.</a></li><li><a class="nounderline abstract_t">Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945.</a></li><li><a class="nounderline abstract_t">Denburg MR, Kumar J, Jemielita T, et al. Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study. J Am Soc Nephrol 2016; 27:543.</a></li><li><a class="nounderline abstract_t">Krempien B, Mehls O, Ritz E. Morphological studies on pathogenesis of epiphyseal slipping in uremic children. Virchows Arch A Pathol Anat Histol 1974; 362:129.</a></li><li><a class="nounderline abstract_t">Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990; 38:931.</a></li><li><a class="nounderline abstract_t">Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342:1478.</a></li><li><a class="nounderline abstract_t">Eifinger F, Wahn F, Querfeld U, et al. Coronary artery calcifications in children and young adults treated with renal replacement therapy. Nephrol Dial Transplant 2000; 15:1892.</a></li><li><a class="nounderline abstract_t">Lumpaopong A, Mathew AV, John E, et al. Early coronary calcification in children and young adults with end-stage renal disease. Transplant Proc 2007; 39:37.</a></li><li><a class="nounderline abstract_t">Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106:100.</a></li><li><a class="nounderline abstract_t">Civilibal M, Caliskan S, Adaletli I, et al. Coronary artery calcifications in children with end-stage renal disease. Pediatr Nephrol 2006; 21:1426.</a></li><li><a class="nounderline abstract_t">Paoli S, Mitsnefes MM. Coronary artery calcification and cardiovascular disease in children with chronic kidney disease. Curr Opin Pediatr 2014; 26:193.</a></li><li><a class="nounderline abstract_t">Shroff RC, McNair R, Figg N, et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008; 118:1748.</a></li><li><a class="nounderline abstract_t">Shroff RC, Shah V, Hiorns MP, et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 2008; 23:3263.</a></li><li><a class="nounderline abstract_t">Shroff RC, Donald AE, Hiorns MP, et al. Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol 2007; 18:2996.</a></li><li><a class="nounderline abstract_t">Groothoff JW, Grootenhuis MA, Offringa M, et al. Social consequences in adult life of end-stage renal disease in childhood. J Pediatr 2005; 146:512.</a></li><li><a class="nounderline abstract_t">Srivaths PR, Goldstein SL, Silverstein DM, et al. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol 2011; 26:945.</a></li><li><a class="nounderline abstract_t">McAlister L, Pugh P, Greenbaum L, et al. The dietary management of calcium and phosphate in children with CKD stages 2-5 and on dialysis-clinical practice recommendation from the Pediatric Renal Nutrition Taskforce. Pediatr Nephrol 2020; 35:501.</a></li><li><a class="nounderline abstract_t">Soeiro EMD, Castro L, Menezes R, et al. Association of parathormone and alkaline phosphatase with bone turnover and mineralization in children with CKD on dialysis: effect of age, gender, and race. Pediatr Nephrol 2020; 35:1297.</a></li><li><a class="nounderline abstract_t">Ziólkowska H, Pańiczyk-Tomaszewska M, Debiński A, et al. Bone biopsy results and serum bone turnover parameters in uremic children. Acta Paediatr 2000; 89:666.</a></li><li><a class="nounderline abstract_t">Waller S, Shroff R, Freemont AJ, Rees L. Bone histomorphometry in children prior to commencing renal replacement therapy. Pediatr Nephrol 2008; 23:1523.</a></li><li><a class="nounderline abstract_t">Wesseling-Perry K, Pereira RC, Tseng CH, et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol 2012; 7:146.</a></li><li><a class="nounderline abstract_t">Andrade MC, Carvalhaes JT, Carvalho AB, et al. Bone mineral density and bone histomorphometry in children on long-term dialysis. Pediatr Nephrol 2007; 22:1767.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; :S1.</a></li><li><a class="nounderline abstract_t">Portale AA, Wolf M, Jüppner H, et al. Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol 2014; 9:344.</a></li><li><a class="nounderline abstract_t">Menon S, Valentini RP, Hidalgo G, et al. Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease. Pediatr Nephrol 2008; 23:1831.</a></li><li><a class="nounderline abstract_t">Bakkaloglu SA, Bacchetta J, Lalayiannis AD, et al. Bone evaluation in paediatric chronic kidney disease: clinical practice points from the European Society for Paediatric Nephrology CKD-MBD and Dialysis working groups and CKD-MBD working group of the ERA-EDTA. Nephrol Dial Transplant 2021; 36:413.</a></li><li><a class="nounderline abstract_t">National Kidney Foundation. K/DOQI clinical practice guidelines for nutrition in children with CKD: 2008 Update. Bone mineral and vitamin D requirements and therapy. Am J Kidney Dis 2009; 53:S61.</a></li><li><a class="nounderline abstract_t">Klaus G, Watson A, Edefonti A, et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 2006; 21:151.</a></li><li><a class="nounderline abstract_t">Shroff R, Wan M, Nagler EV, et al. Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2-5 and on dialysis. Nephrol Dial Transplant 2017; 32:1098.</a></li><li><a class="nounderline abstract_t">Haffner D, Leifheit-Nestler M. Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels. Pediatr Nephrol 2020; 35:485.</a></li><li><a class="nounderline abstract_t">Portale AA, Booth BE, Halloran BP, Morris RC Jr. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984; 73:1580.</a></li><li><a class="nounderline abstract_t">Turner C, Compston J, Mak RH, et al. Bone turnover and 1,25-dihydroxycholecalciferol during treatment with phosphate binders. Kidney Int 1988; 33:989.</a></li><li><a class="nounderline abstract_t">Wingen AM, Fabian-Bach C, Schaefer F, Mehls O. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet 1997; 349:1117.</a></li><li><a class="nounderline abstract_t">Kist-van Holthe tot Echten JE, Nauta J, Hop WC, et al. Protein restriction in chronic renal failure. Arch Dis Child 1993; 68:371.</a></li><li><a class="nounderline abstract_t">Jureidini KF, Hogg RJ, van Renen MJ, et al. Evaluation of long-term aggressive dietary management of chronic renal failure in children. Pediatr Nephrol 1990; 4:1.</a></li><li><a class="nounderline abstract_t">Uauy RD, Hogg RJ, Brewer ED, et al. Dietary protein and growth in infants with chronic renal insufficiency: a report from the Southwest Pediatric Nephrology Study Group and the University of California, San Francisco. Pediatr Nephrol 1994; 8:45.</a></li><li><a class="nounderline abstract_t">Tamanaha K, Mak RH, Rigden SP, et al. Long-term suppression of hyperparathyroidism by phosphate binders in uremic children. Pediatr Nephrol 1987; 1:145.</a></li><li><a class="nounderline abstract_t">Andreoli SP, Dunson JW, Bergstein JM. Calcium carbonate is an effective phosphorus binder in children with chronic renal failure. Am J Kidney Dis 1987; 9:206.</a></li><li><a class="nounderline abstract_t">Geary DF, Hodson EM, Craig JC. Interventions for bone disease in children with chronic kidney disease. Cochrane Database Syst Rev 2010; :CD008327.</a></li><li><a class="nounderline abstract_t">Andreoli SP, Bergstein JM, Sherrard DJ. Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med 1984; 310:1079.</a></li><li><a class="nounderline abstract_t">Hahn D, Hodson EM, Craig JC. Interventions for metabolic bone disease in children with chronic kidney disease. Cochrane Database Syst Rev 2015; :CD008327.</a></li><li><a class="nounderline abstract_t">Mahdavi H, Kuizon BD, Gales B, et al. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children. Pediatr Nephrol 2003; 18:1260.</a></li><li><a class="nounderline abstract_t">Pieper AK, Haffner D, Hoppe B, et al. A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. Am J Kidney Dis 2006; 47:625.</a></li><li><a class="nounderline abstract_t">Fathallah-Shaykh S, Drozdz D, Flynn J, et al. Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease. Pediatr Nephrol 2018; 33:325.</a></li><li><a class="nounderline abstract_t">Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19:429.</a></li><li><a class="nounderline abstract_t">Kumar J, McDermott K, Abraham AG, et al. Prevalence and correlates of 25-hydroxyvitamin D deficiency in the Chronic Kidney Disease in Children (CKiD) cohort. Pediatr Nephrol 2016; 31:121.</a></li><li><a class="nounderline abstract_t">Seeherunvong W, Abitbol CL, Chandar J, et al. Vitamin D insufficiency and deficiency in children with early chronic kidney disease. J Pediatr 2009; 154:906.</a></li><li><a class="nounderline abstract_t">Ali FN, Arguelles LM, Langman CB, Price HE. Vitamin D deficiency in children with chronic kidney disease: uncovering an epidemic. Pediatrics 2009; 123:791.</a></li><li><a class="nounderline abstract_t">Kalkwarf HJ, Denburg MR, Strife CF, et al. Vitamin D deficiency is common in children and adolescents with chronic kidney disease. Kidney Int 2012; 81:690.</a></li><li><a class="nounderline abstract_t">Shroff R, Aitkenhead H, Costa N, et al. Normal 25-Hydroxyvitamin D Levels Are Associated with Less Proteinuria and Attenuate Renal Failure Progression in Children with CKD. J Am Soc Nephrol 2016; 27:314.</a></li><li><a class="nounderline abstract_t">Shroff R, Wan M, Nagler EV, et al. Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis. Nephrol Dial Transplant 2017; 32:1114.</a></li><li><a class="nounderline abstract_t">Chesney RW, Moorthy AV, Eisman JA, et al. Increased growth after long-term oral 1alpha,25-vitamin D3 in childhood renal osteodystrophy. N Engl J Med 1978; 298:238.</a></li><li><a class="nounderline abstract_t">Waller S, Ledermann S, Trompeter R, et al. Catch-up growth with normal parathyroid hormone levels in chronic renal failure. Pediatr Nephrol 2003; 18:1236.</a></li><li><a class="nounderline abstract_t">Rees L. What parathyroid hormone levels should we aim for in children with stage 5 chronic kidney disease; what is the evidence? Pediatr Nephrol 2008; 23:179.</a></li><li><a class="nounderline abstract_t">Borzych D, Rees L, Ha IS, et al. The bone and mineral disorder of children undergoing chronic peritoneal dialysis. Kidney Int 2010; 78:1295.</a></li><li><a class="nounderline abstract_t">Bacchetta J. Treatment of hyperphosphatemia: the dangers of high PTH levels. Pediatr Nephrol 2020; 35:493.</a></li><li><a class="nounderline abstract_t">Seeherunvong W, Nwobi O, Abitbol CL, et al. Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatr Nephrol 2006; 21:1434.</a></li><li><a class="nounderline abstract_t">Webb NJA, Lerner G, Warady BA, et al. Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease. Pediatr Nephrol 2017; 32:1221.</a></li><li><a class="nounderline abstract_t">Greenbaum LA, Benador N, Goldstein SL, et al. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Am J Kidney Dis 2007; 49:814.</a></li><li><a class="nounderline abstract_t">Warady BA, Iles JN, Ariceta G, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis. Pediatr Nephrol 2019; 34:475.</a></li><li><a class="nounderline abstract_t">Alharthi AA, Kamal NM, Abukhatwah MW, Sherief LM. Cinacalcet in pediatric and adolescent chronic kidney disease: a single-center experience. Medicine (Baltimore) 2015; 94:e401.</a></li><li><a class="nounderline abstract_t">Muscheites J, Wigger M, Drueckler E, et al. Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatr Nephrol 2008; 23:1823.</a></li><li><a class="nounderline abstract_t">Silverstein DM, Kher KK, Moudgil A, et al. Cinacalcet is efficacious in pediatric dialysis patients. Pediatr Nephrol 2008; 23:1817.</a></li><li><a class="nounderline abstract_t">Joseph C, Shah S, Geer J, et al. Cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients below age 5 years . Clin Nephrol 2019; 92:279.</a></li><li><a class="nounderline abstract_t">Warady BA, Ng E, Bloss L, et al. Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis. Pediatr Nephrol 2020; 35:1679.</a></li><li><a class="nounderline abstract_t">Bacchetta J, Schmitt CP, Ariceta G, et al. Cinacalcet use in paediatric dialysis: a position statement from the European Society for Paediatric Nephrology and the Chronic Kidney Disease-Mineral and Bone Disorders Working Group of the ERA-EDTA. Nephrol Dial Transplant 2020; 35:47.</a></li></ol></div><div id="topicVersionRevision">Topic 6092 Version 48.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16641930" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26139439" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4824457" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Morphological studies on pathogenesis of epiphyseal slipping in uremic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2266678" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Soft tissue calcification in pediatric patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10816185" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11071992" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Coronary artery calcifications in children and young adults treated with renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17275470" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Early coronary calcification in children and young adults with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12093777" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16821026" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Coronary artery calcifications in children with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24632542" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Coronary artery calcification and cardiovascular disease in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18838561" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18463323" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17942964" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mineral metabolism and vascular damage in children on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15812455" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Social consequences in adult life of end-stage renal disease in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21359960" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31667620" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The dietary management of calcium and phosphate in children with CKD stages 2-5 and on dialysis-clinical practice recommendation from the Pediatric Renal Nutrition Taskforce.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32157445" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Association of parathormone and alkaline phosphatase with bone turnover and mineralization in children with CKD on dialysis: effect of age, gender, and race.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10914959" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Bone biopsy results and serum bone turnover parameters in uremic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18481109" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bone histomorphometry in children prior to commencing renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22052943" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Early skeletal and biochemical alterations in pediatric chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17680276" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Bone mineral density and bone histomorphometry in children on long-term dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19644521" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24311704" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Disordered FGF23 and mineral metabolism in children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18575896" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33245331" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Bone evaluation in paediatric chronic kidney disease: clinical practice points from the European Society for Paediatric Nephrology CKD-MBD and Dialysis working groups and CKD-MBD working group of the ERA-EDTA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Bone mineral and vitamin D requirements and therapy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16247644" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28873969" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2-5 and on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31823044" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6547151" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3392888" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bone turnover and 1,25-dihydroxycholecalciferol during treatment with phosphate binders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9113009" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8466240" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Protein restriction in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2206872" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Evaluation of long-term aggressive dietary management of chronic renal failure in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8142225" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Dietary protein and growth in infants with chronic renal insufficiency: a report from the Southwest Pediatric Nephrology Study Group and the University of California, San Francisco.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3153271" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Long-term suppression of hyperparathyroidism by phosphate binders in uremic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3826069" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Calcium carbonate is an effective phosphorus binder in children with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20091666" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Interventions for bone disease in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6708989" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26561037" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Interventions for metabolic bone disease in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14586677" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Sevelamer hydrochloride: an effective phosphate binder in dialyzed children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16564940" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28900759" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15040831" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26307635" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prevalence and correlates of 25-hydroxyvitamin D deficiency in the Chronic Kidney Disease in Children (CKiD) cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19230902" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Vitamin D insufficiency and deficiency in children with early chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19255004" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Vitamin D deficiency in children with chronic kidney disease: uncovering an epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22205356" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Vitamin D deficiency is common in children and adolescents with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26069294" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Normal 25-Hydroxyvitamin D Levels Are Associated with Less Proteinuria and Attenuate Renal Failure Progression in Children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28873971" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/201843" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Increased growth after long-term oral 1alpha,25-vitamin D3 in childhood renal osteodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14586680" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Catch-up growth with normal parathyroid hormone levels in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18043947" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : What parathyroid hormone levels should we aim for in children with stage 5 chronic kidney disease; what is the evidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20811335" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The bone and mineral disorder of children undergoing chronic peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31696357" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Treatment of hyperphosphatemia: the dangers of high PTH levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16900383" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28332096" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17533024" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30506144" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25590845" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cinacalcet in pediatric and adolescent chronic kidney disease: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18504621" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18288502" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cinacalcet is efficacious in pediatric dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31587754" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients below age 5 years .</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32367309" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31641778" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cinacalcet use in paediatric dialysis: a position statement from the European Society for Paediatric Nephrology and the Chronic Kidney Disease-Mineral and Bone Disorders Working Group of the ERA-EDTA.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
